Lung Cancer News

Johns Hopkins Kimmel Cancer Center researchers have developed a blood test designed to screen for the eight most common cancer types.

CHICAGO — Socioeconomic factors influenced whether patients with stage IV non-small cell lung cancer refused cancer treatment, according to study results presented at American Association for Cancer Research Annual Meeting.

The Lung Cancer Registry has launched a study designed to assess the side effects associated with use of immune checkpoint inhibitors for the treatment for non-small cell lung cancer.

CHICAGO — The addition of atezolizumab to bevacizumab plus chemotherapy extended PFS for patients with non-small cell lung cancer, according to results from the IMpower150 study presented at American Association for Cancer Research Annual Meeting.

CHICAGO — Higher tumor mutational burden appeared associated with greater response to treatment with nivolumab plus ipilimumab among patients with advanced non-small cell lung cancer, according to results from the CheckMate 568 study presented at American Association for Cancer Research Annual Meeting.

CHICAGO — Neoadjuvant therapy with the anti-PD-1 therapy nivolumab induced responses among nearly half of patients with resectable lung cancer, according to study results presented at American Association for Cancer Research Annual Meeting.

CHICAGO — Immunotherapy with nivolumab plus ipilimumab significantly prolonged PFS compared with standard chemotherapy among patients with newly diagnosed advanced non-small cell lung cancer with high tumor mutational burden, according to results of the randomized phase 3 CheckMate -227 trial presented at American Association for Cancer Research Annual Meeting.

CHICAGO — The addition of the anti-PD-1 therapy pembrolizumab to chemotherapy significantly improved outcomes among patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer who do not harbor EGFR or ALK alterations, according to results of the randomized phase 3 KEYNOTE-189 trial presented at American Association for Cancer Research Annual Meeting.

CHICAGO — Lorlatinib demonstrated antitumor activity among patients with non-small cell lung cancer and ALK kinase domain mutations, according to study results presented at American Association for Cancer Research Annual Meeting.

Patients with head and neck cancers appeared significantly more likely to receive opioid prescriptions than those who had lung cancer or colon cancer, according to a published research letter.